Diane Seimetz Selected Research

Antigens

10/2010

Development and approval of the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3) as a targeted cancer immunotherapy.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Diane Seimetz Research Topics

Disease

6	Ascites 06/2014 - 03/2010
5	Neoplasms (Cancer) 12/2013 - 03/2010
3	Carcinoma (Carcinomatosis) 01/2011 - 03/2010
1	Wounds and Injuries (Trauma) 01/2018
1	Stomach Neoplasms (Stomach Cancer) 12/2013

Drug/Important Bio-Agent (IBA)

6	catumaxomabIBA 06/2014 - 03/2010
4	Epithelial Cell Adhesion MoleculeIBA 12/2013 - 03/2010
2	CD3 ComplexIBA 01/2011 - 10/2010
1	Biomarkers (Surrogate Marker)IBA 06/2014
1	Neoplasm Antigens (Tumor Antigens)IBA 12/2013
1	PlatinumIBA 12/2013
1	Monoclonal AntibodiesIBA 01/2011
1	AntigensIBA 10/2010

Therapy/Procedure

3	Therapeutics 01/2018 - 10/2010
2	Immunotherapy 05/2012 - 10/2010
1	Physical Therapy Modalities (Physical Therapy Technique) 01/2018
1	Drug Therapy (Chemotherapy) 12/2013